Litcius/Paper detail

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Michael C. Heinrich, Robin L. Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon‐Koo Kang, Philippe A. Cassier, Olivier Mir, Ferry A.L.M. Eskens, William D. Tap, Piotr Rutkowski, Sant P. Chawla, Jonathan C. Trent, Meera Tugnait, Erica N Evans, Tamieka Lauz, Teresa Zhou, Maria Roche, Beni B. Wolf, Sebastian Bauer, Suzanne George

2020The Lancet Oncology305 citationsDOI

Topics & Concepts

PDGFRAImatinibGiSTStromal cellMedicineTyrosine-kinase inhibitorGastrointestinal tractOncologyInternal medicineTyrosine kinaseStromal tumorCancer researchCancerReceptorMyeloid leukemiaGastrointestinal Tumor Research and TreatmentGastrointestinal Bleeding Diagnosis and TreatmentIgG4-Related and Inflammatory Diseases
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial | Litcius